Phase II Clinical Trial of Ad-SGE-REIC for Malignant Pleural Mesothelioma
First written in FY2019-Q1. 2 of 4 entries say "Restated". Latest entry: FY2021-Q2.
No other company in this theme has enough history to compare yet.
- FY2021-Q2DroppedAnnual report
「Ad-SGE-REIC, a gene therapy product, was selected for the NexTEP industry-academia joint practical application development program of the Japan Science and Technology Agency, and the company had been conducting a clinical trial for malignant pleural mesothelioma, at the Phase II development stage. However, the company determined that it would be difficult to achieve the product profile initially established and discontinued development of the product.」
Ad-SGE-REIC had been in Phase II clinical trials, but development was discontinued because the company determined that it would be difficult to achieve the product profile. - FY2019RestatedAnnual report
「The company began a Phase II clinical trial of the gene therapy Ad-SGE-REIC for malignant pleural mesothelioma in June 2018」
The company continues to state that it began a Phase II clinical trial of Ad-SGE-REIC for malignant pleural mesothelioma in June 2018. - FY2019-Q2RestatedAnnual report
「The company began a Phase II clinical trial of the gene therapy Ad-SGE-REIC for malignant pleural mesothelioma in June 2018,」
The company continues to state that it began a Phase II clinical trial of Ad-SGE-REIC for malignant pleural mesothelioma in June 2018. - FY2019-Q1First statedAnnual report
「We began a Phase II clinical trial in June 2018 for the gene therapy Ad-SGE-REIC in patients with malignant pleural mesothelioma.」
A Phase II clinical trial of Ad-SGE-REIC for malignant pleural mesothelioma began in June 2018.